Pall corporation offers fully integrated end-to-end bioprocessing solutions for gene therapy, from early process development projects to commercialization. Our dedicated teams of experts will work closely with you to overcome development and viral vector manufacturing obstacles to accelerate delivery of commercially viable gene therapies to patients.

Our extensive portfolio of upstream, downstream, and formulation and filling technologies is suitable for manufacturing different viral vector types in adherent or suspension-based processes.

Whether that means quickly developing a process, helping you ensure regulatory compliance, or making existing processes easier, faster and better, we are ready to work with you to address your process needs and accelerate your speed to market.

Please visit www.pall.com/en/biotech/gene-therapy